These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 27993802)

  • 1. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.
    Delyon J; Brunet-Possenti F; Leonard-Louis S; Arangalage D; Baudet M; Baroudjian B; Lebbe C; Hervier B;
    Ann Rheum Dis; 2019 Nov; 78(11):e129. PubMed ID: 30242031
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.
    van Holstein Y; Kapiteijn E; Bastiaannet E; van den Bos F; Portielje J; de Glas NA
    Drugs Aging; 2019 Oct; 36(10):927-938. PubMed ID: 31317421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities of checkpoint inhibitors: causes and management.
    Postow MA
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
    [No Abstract]   [Full Text] [Related]  

  • 17. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
    Kennedy LC; Bhatia S; Thompson JA; Grivas P
    J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.